Vestal Point Capital LP acquired a new stake in shares of Bruker Co. (NASDAQ:BRKR - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 125,000 shares of the medical research company's stock, valued at approximately $8,632,000. Vestal Point Capital LP owned 0.08% of Bruker at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of the company. Tidal Investments LLC purchased a new stake in Bruker in the 1st quarter worth about $218,000. Virtu Financial LLC purchased a new position in shares of Bruker in the first quarter worth about $251,000. Atria Investments Inc bought a new stake in shares of Bruker in the first quarter valued at approximately $1,142,000. Cetera Investment Advisers lifted its stake in shares of Bruker by 350.0% during the 1st quarter. Cetera Investment Advisers now owns 33,131 shares of the medical research company's stock valued at $3,112,000 after buying an additional 25,768 shares in the last quarter. Finally, Cetera Advisors LLC bought a new position in Bruker in the 1st quarter worth approximately $693,000. 79.52% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on BRKR shares. Wells Fargo & Company lowered their target price on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating on the stock in a report on Wednesday, November 6th. Citigroup decreased their price objective on Bruker from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. Wolfe Research downgraded Bruker from an "outperform" rating to a "peer perform" rating in a research note on Monday, September 30th. Barclays lowered their price target on shares of Bruker from $75.00 to $69.00 and set an "overweight" rating on the stock in a report on Wednesday, November 6th. Finally, TD Cowen decreased their target price on shares of Bruker from $72.00 to $70.00 and set a "hold" rating on the stock in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $79.36.
Check Out Our Latest Stock Report on BRKR
Insiders Place Their Bets
In related news, CEO Frank H. Laukien acquired 100,000 shares of Bruker stock in a transaction dated Monday, November 18th. The shares were purchased at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the purchase, the chief executive officer now owns 38,439,563 shares of the company's stock, valued at $1,927,359,688.82. This represents a 0.26 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 28.30% of the company's stock.
Bruker Price Performance
Shares of NASDAQ:BRKR traded down $0.43 during trading on Friday, reaching $57.95. The company had a trading volume of 805,901 shares, compared to its average volume of 1,114,335. Bruker Co. has a 12 month low of $48.07 and a 12 month high of $94.86. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $8.79 billion, a P/E ratio of 27.91, a price-to-earnings-growth ratio of 3.92 and a beta of 1.20. The company has a fifty day moving average of $60.82 and a two-hundred day moving average of $64.20.
Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing analysts' consensus estimates of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to analysts' expectations of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. The company's revenue for the quarter was up 16.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.74 EPS. Equities research analysts forecast that Bruker Co. will post 2.4 earnings per share for the current year.
Bruker Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Monday, December 2nd will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date of this dividend is Monday, December 2nd. Bruker's payout ratio is currently 9.62%.
About Bruker
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Featured Articles
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
